 Andrea Griesinger
Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ependymoma | 13 | 2024 | 161 | 3.840 |
Why?
| | Infratentorial Neoplasms | 6 | 2024 | 55 | 2.110 |
Why?
| | Brain Neoplasms | 8 | 2024 | 1143 | 1.140 |
Why?
| | Immunophenotyping | 2 | 2017 | 310 | 0.900 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2019 | 69 | 0.780 |
Why?
| | Medulloblastoma | 6 | 2022 | 192 | 0.730 |
Why?
| | Cerebellar Neoplasms | 5 | 2022 | 151 | 0.650 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 208 | 0.590 |
Why?
| | Supratentorial Neoplasms | 1 | 2018 | 16 | 0.580 |
Why?
| | Transcription Factor RelA | 1 | 2018 | 83 | 0.560 |
Why?
| | Nuclear Proteins | 3 | 2017 | 659 | 0.510 |
Why?
| | Myeloid Cells | 2 | 2015 | 141 | 0.500 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 195 | 0.500 |
Why?
| | Gene Expression Regulation, Neoplastic | 7 | 2022 | 1344 | 0.490 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 314 | 0.480 |
Why?
| | Biomarkers, Tumor | 3 | 2018 | 1173 | 0.460 |
Why?
| | NF-kappa B | 1 | 2017 | 665 | 0.430 |
Why?
| | STAT3 Transcription Factor | 1 | 2015 | 194 | 0.420 |
Why?
| | Gene Expression Profiling | 8 | 2024 | 1688 | 0.410 |
Why?
| | Cell Line, Tumor | 9 | 2020 | 3202 | 0.360 |
Why?
| | Interleukin-6 | 1 | 2015 | 720 | 0.360 |
Why?
| | Cell Proliferation | 6 | 2019 | 2375 | 0.350 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1933 | 0.350 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4057 | 0.320 |
Why?
| | Phenotype | 3 | 2024 | 3074 | 0.320 |
Why?
| | Child | 17 | 2024 | 20785 | 0.290 |
Why?
| | Chromosomes | 2 | 2024 | 100 | 0.270 |
Why?
| | Antineoplastic Agents | 4 | 2020 | 2054 | 0.260 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2019 | 131 | 0.240 |
Why?
| | Chloroquine | 2 | 2017 | 51 | 0.240 |
Why?
| | Craniopharyngioma | 2 | 2017 | 74 | 0.240 |
Why?
| | Neurofibroma, Plexiform | 1 | 2023 | 9 | 0.220 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2017 | 209 | 0.210 |
Why?
| | Neurofibromatosis 1 | 1 | 2023 | 47 | 0.210 |
Why?
| | Fluorouracil | 1 | 2024 | 198 | 0.210 |
Why?
| | Autophagy | 2 | 2017 | 266 | 0.210 |
Why?
| | Genes, myc | 2 | 2020 | 49 | 0.200 |
Why?
| | Indoles | 2 | 2017 | 384 | 0.200 |
Why?
| | Tumor Microenvironment | 4 | 2023 | 631 | 0.190 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2019 | 812 | 0.190 |
Why?
| | Humans | 28 | 2024 | 129266 | 0.190 |
Why?
| | Sulfonamides | 2 | 2017 | 495 | 0.190 |
Why?
| | Signal Transduction | 1 | 2015 | 4926 | 0.190 |
Why?
| | Chromosome Aberrations | 2 | 2023 | 148 | 0.180 |
Why?
| | Mice | 7 | 2024 | 16915 | 0.180 |
Why?
| | Apoptosis | 4 | 2019 | 2499 | 0.180 |
Why?
| | Central Nervous System Neoplasms | 1 | 2023 | 146 | 0.180 |
Why?
| | Tumor Cells, Cultured | 2 | 2019 | 942 | 0.170 |
Why?
| | Glioma | 1 | 2024 | 347 | 0.170 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 70 | 0.170 |
Why?
| | Cytokines | 3 | 2017 | 2013 | 0.160 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 252 | 0.160 |
Why?
| | Pyrimidinones | 1 | 2020 | 103 | 0.160 |
Why?
| | Immunotherapy, Adoptive | 2 | 2023 | 295 | 0.160 |
Why?
| | Pyrazoles | 2 | 2020 | 404 | 0.160 |
Why?
| | Mice, SCID | 1 | 2019 | 350 | 0.150 |
Why?
| | Deoxycytidine | 1 | 2020 | 165 | 0.150 |
Why?
| | SMARCB1 Protein | 1 | 2019 | 29 | 0.150 |
Why?
| | Osteomyelitis | 1 | 2020 | 121 | 0.150 |
Why?
| | Cohort Studies | 4 | 2018 | 5409 | 0.150 |
Why?
| | Cell Cycle Proteins | 2 | 2020 | 584 | 0.150 |
Why?
| | Animals | 9 | 2024 | 35309 | 0.150 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 588 | 0.140 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 275 | 0.140 |
Why?
| | Teratoma | 1 | 2019 | 103 | 0.140 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2018 | 193 | 0.140 |
Why?
| | Cyst Fluid | 1 | 2017 | 25 | 0.140 |
Why?
| | Rhabdoid Tumor | 1 | 2019 | 95 | 0.140 |
Why?
| | Survival Rate | 2 | 2019 | 1869 | 0.140 |
Why?
| | Epigenesis, Genetic | 2 | 2021 | 616 | 0.130 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 30 | 0.130 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2020 | 432 | 0.130 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2019 | 327 | 0.130 |
Why?
| | Prognosis | 4 | 2018 | 3773 | 0.130 |
Why?
| | Histones | 1 | 2021 | 588 | 0.130 |
Why?
| | Microarray Analysis | 4 | 2017 | 117 | 0.130 |
Why?
| | Receptor, ErbB-2 | 1 | 2018 | 326 | 0.120 |
Why?
| | Pituitary Neoplasms | 1 | 2017 | 179 | 0.120 |
Why?
| | Transcriptional Activation | 1 | 2017 | 367 | 0.120 |
Why?
| | EGF Family of Proteins | 1 | 2015 | 16 | 0.120 |
Why?
| | Receptor, EphA2 | 1 | 2015 | 19 | 0.120 |
Why?
| | Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2015 | 21 | 0.120 |
Why?
| | Receptor, ErbB-3 | 1 | 2015 | 44 | 0.120 |
Why?
| | Transcriptome | 4 | 2023 | 874 | 0.120 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 390 | 0.120 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2015 | 86 | 0.120 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2017 | 756 | 0.110 |
Why?
| | src-Family Kinases | 1 | 2015 | 95 | 0.110 |
Why?
| | RNA, Messenger | 3 | 2017 | 2703 | 0.110 |
Why?
| | Receptors, IgG | 1 | 2013 | 73 | 0.110 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1204 | 0.100 |
Why?
| | Astrocytoma | 1 | 2013 | 115 | 0.100 |
Why?
| | HLA-DR Antigens | 1 | 2013 | 223 | 0.100 |
Why?
| | Monocytes | 1 | 2015 | 551 | 0.100 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 333 | 0.100 |
Why?
| | Central Nervous System | 1 | 2014 | 253 | 0.100 |
Why?
| | Inflammation Mediators | 1 | 2015 | 505 | 0.100 |
Why?
| | ErbB Receptors | 1 | 2015 | 605 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2024 | 10202 | 0.090 |
Why?
| | Child, Preschool | 4 | 2020 | 10459 | 0.090 |
Why?
| | Phosphorylation | 1 | 2015 | 1710 | 0.090 |
Why?
| | Glioblastoma | 1 | 2013 | 322 | 0.080 |
Why?
| | Neoplastic Stem Cells | 1 | 2014 | 379 | 0.080 |
Why?
| | Transcription Factors | 2 | 2017 | 1647 | 0.080 |
Why?
| | Adolescent | 4 | 2018 | 20313 | 0.080 |
Why?
| | Epilepsy | 1 | 2013 | 322 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2018 | 4887 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2013 | 958 | 0.070 |
Why?
| | Infant | 2 | 2018 | 8975 | 0.070 |
Why?
| | Azepines | 2 | 2019 | 88 | 0.060 |
Why?
| | Triazoles | 2 | 2019 | 151 | 0.060 |
Why?
| | Mice, Nude | 2 | 2019 | 682 | 0.060 |
Why?
| | Drug Synergism | 2 | 2017 | 370 | 0.060 |
Why?
| | Male | 7 | 2020 | 63512 | 0.060 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 13 | 0.050 |
Why?
| | Young Adult | 2 | 2018 | 12391 | 0.050 |
Why?
| | Intelligence Tests | 1 | 2023 | 57 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2020 | 2117 | 0.050 |
Why?
| | RNA, Small Nuclear | 1 | 2023 | 35 | 0.050 |
Why?
| | Quality of Life | 1 | 2015 | 2687 | 0.050 |
Why?
| | Female | 7 | 2020 | 68551 | 0.050 |
Why?
| | Cranial Irradiation | 1 | 2023 | 67 | 0.050 |
Why?
| | Cell Survival | 2 | 2017 | 1075 | 0.050 |
Why?
| | Adult | 3 | 2023 | 35495 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 621 | 0.050 |
Why?
| | Brain | 1 | 2013 | 2669 | 0.050 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2023 | 201 | 0.050 |
Why?
| | Epigenomics | 1 | 2021 | 110 | 0.040 |
Why?
| | Symptom Flare Up | 1 | 2020 | 38 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 187 | 0.040 |
Why?
| | Drug Substitution | 1 | 2020 | 51 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 178 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2020 | 70 | 0.040 |
Why?
| | Survival Analysis | 1 | 2023 | 1269 | 0.040 |
Why?
| | Homozygote | 1 | 2020 | 193 | 0.040 |
Why?
| | Survivors | 1 | 2023 | 457 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2023 | 1014 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 704 | 0.040 |
Why?
| | Cell Self Renewal | 1 | 2019 | 53 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2020 | 372 | 0.040 |
Why?
| | Injections, Intraventricular | 1 | 2018 | 55 | 0.040 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2019 | 130 | 0.040 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 280 | 0.040 |
Why?
| | Drug Approval | 1 | 2018 | 87 | 0.040 |
Why?
| | Receptors, HIV | 1 | 2017 | 25 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2018 | 149 | 0.040 |
Why?
| | Mucin-1 | 1 | 2017 | 19 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2018 | 141 | 0.040 |
Why?
| | Receptors, Interleukin-6 | 1 | 2017 | 37 | 0.040 |
Why?
| | Cytogenetic Analysis | 1 | 2017 | 32 | 0.040 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 55 | 0.030 |
Why?
| | Cellular Senescence | 1 | 2019 | 181 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 108 | 0.030 |
Why?
| | RNA | 1 | 2023 | 880 | 0.030 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2017 | 91 | 0.030 |
Why?
| | Benzodiazepinones | 1 | 2016 | 16 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 827 | 0.030 |
Why?
| | Urea | 1 | 2016 | 76 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 305 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2630 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 117 | 0.030 |
Why?
| | Amphiregulin | 1 | 2015 | 24 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 758 | 0.030 |
Why?
| | Chromatin | 1 | 2019 | 478 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 645 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 299 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 851 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 939 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 529 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 328 | 0.030 |
Why?
| | Up-Regulation | 1 | 2015 | 839 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 947 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2014 | 756 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1204 | 0.020 |
Why?
| | Cell Cycle | 1 | 2014 | 589 | 0.020 |
Why?
| | Gene Expression | 1 | 2015 | 1466 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2017 | 1446 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1691 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1556 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2063 | 0.020 |
Why?
| | Risk Factors | 1 | 2018 | 9745 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2015 | 5736 | 0.010 |
Why?
| | Mutation | 1 | 2014 | 3710 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7055 | 0.010 |
Why?
| | Aged | 1 | 2013 | 22032 | 0.010 |
Why?
| | Middle Aged | 1 | 2013 | 31090 | 0.010 |
Why?
|
|
Griesinger's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|